Loading institutional data...
Loading institutional data...
Held by 419 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $178.19 today, the market must believe free cash flow compounds 28.9%/yr for a decade (off $107M normalized FCF).
The market's 28.9% is more conservative than its 9-yr track record.
2-stage DCF · 0.06B shares · net debt -$24M
mean 67.1% · volatility σ 95% · implied rate exceeded in 6/9 yrs
Central path = implied 28.9%/yr growth; shaded band = ±1σ (95%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $94M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 2%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~4.0% on $542M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $738.3M 100.0% | $634.4M 100.0% | $632.4M 100.0% | $801.5M 100.0% | $670.5M 100.0% | $366.3M 100.0% | $270.2M 100.0% | $194.0M 100.0% | $141.2M 100.0% | $104.5M 100.0% |
| Cost of Revenue | $352.0M 47.7% | $359.8M 56.7% | $353.9M 56.0% | $345.8M 43.1% | $279.3M 41.7% | $156.6M 42.8% | $119.1M 44.1% | $86.5M 44.6% | $67.0M 47.5% | $47.1M 45.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $67.0M 47.5% | $47.1M 45.1% |
| Research & Development | $54.2M 7.3% | $43.2M 6.8% | $42.7M 6.8% | $43.9M 5.5% | $34.3M 5.1% | $20.2M 5.5% | $19.4M 7.2% | $15.8M 8.2% | $8.7M 6.1% | $7.4M 7.0% |
| Selling, General & Admin | $290.5M 39.4% | $263.4M 41.5% | $218.6M 34.6% | $215.8M 26.9% | $183.9M 27.4% | $119.6M 32.7% | $95.6M 35.4% | $65.7M 33.9% | $51.5M 36.5% | $30.9M 29.5% |
| Total Operating Expenses | $683.1M 92.5% | $669.6M 105.5% | $584.7M 92.5% | $576.9M 72.0% | $503.3M 75.1% | $296.4M 80.9% | $234.2M 86.6% | $168.0M 86.6% | $127.2M 90.1% | $88.6M 84.7% |
| Operating Income | $55.2M 7.5% | -$35.1M -5.5% | $47.7M 7.5% | $224.7M 28.0% | $167.2M 24.9% | $69.8M 19.1% | $36.1M 13.4% | $26.0M 13.4% | $14.0M 9.9% | $16.0M 15.3% |
| Interest Expense | $21.5M 2.9% | $20.7M 3.3% | $2.0M 0.3% | $1.2M 0.1% | $11.3M 1.7% | $10.8M 2.9% | $9.3M 3.4% | $6.7M 3.5% | $6.4M 4.6% | $3.8M 3.6% |
| Other Income (Expense), net | $7.2M 1.0% | $8.1M 1.3% | $9.0M 1.4% | -$5.5M -0.7% | -$13.7M -2.0% | -$10.6M -2.9% | -$9.9M -3.7% | -$4.6M -2.3% | -$6.8M -4.8% | -$4.3M -4.1% |
| Pretax Income | $62.4M 8.5% | -$27.0M -4.3% | $56.7M 9.0% | $219.1M 27.3% | $153.5M 22.9% | $59.2M 16.2% | $26.2M 9.7% | $21.4M 11.0% | $7.2M 5.1% | $11.7M 11.2% |
| Income Tax Expense | $13.5M 1.8% | -$1.5M -0.2% | $21.1M 3.3% | $33.2M 4.1% | $25.3M 3.8% | -$709K -0.2% | $4.7M 1.8% | $4.8M 2.5% | -$21.1M -14.9% | $11K 0.0% |
| Net Income | $48.9M 6.6% | -$25.5M -4.0% | $35.6M 5.6% | $186.0M 23.2% | $128.3M 19.1% | $59.9M 16.4% | $21.4M 7.9% | $16.6M 8.6% | $28.4M 20.1% | $11.7M 11.2% |
| Per Share | ||||||||||
| EPS (Basic) | $0.87 | $-0.46 | $0.64 | $3.35 | $2.33 | $1.14 | $0.44 | $0.38 | $0.74 | $0.35 |
| EPS (Diluted) | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 | $1.11 | $0.44 | $0.37 | $0.72 | $0.34 |
| Weighted Avg Shares (Basic) | 56K | 56K | 56K | 55K | 55K | 53K | 48.3M | 43.8M | 38.2M | 34K |
| Weighted Avg Shares (Diluted) | 57K | 56K | 56K | 57K | 57K | 54K | 49.2M | 45.5M | 39.1M | 34K |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| RGEN | $10.0B | 207.2× | 105.5× | 13.6× | 16.4% | 52.3% | 6.6% | 2.3% | 1.8% | 5.7× | 419 |
Peers = companies sharing RGEN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 71th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 44.6 | 44.1 | 42.8 | 41.7 | 43.1 | 56.0 | 56.7 | 47.7 |
| R&D | 8.2 | 7.2 | 5.5 | 5.1 | 5.5 | 6.8 | 6.8 | 7.3 |
| SG&A | 33.9 | 35.4 | 32.7 | 27.4 | 26.9 | 34.6 | 41.5 | 39.4 |
| Operating Income | 13.4 | 13.4 | 19.1 | 24.9 | 28.0 | 7.5 | -5.5 | 7.5 |
| Income Tax | 2.5 | 1.8 | -0.2 | 3.8 | 4.1 | 3.3 | -0.2 | 1.8 |
| Net Income | 8.6 | 7.9 | 16.4 | 19.1 | 23.2 | 5.6 | -4.0 | 6.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RGEN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.